Completed
A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD neVirapine Extended Release formulation in comparison to 200 mg BID neVirapinE immediate release in combination with Truvada™ in antiretroviral therapy naïve HIV-1 infected patients. (VERxVE study)(Trial number 1100.1486)
Learn MoreCompleted
48-Week Study of GW433908 and Ritonavir or GW433908 Alone, Twice Daily in Pediatric Patients with HIV Infection.
Learn MoreCompleted
Completed
A phase II, multicentre, randomized, double-blind, placebo-controlled, three-Arm study of the anti-CD4 monoclonal antibody TNX-355 with optimized background therapy in treatment-experienced subjects infected with HIV-1. (TNX-355.03)
Learn MoreCompleted
Early access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options (TMC125-C214)
Learn MoreCompleted
An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-Experienced HIV-1 Infected Patients
Learn MoreCompleted
Addition of ezetimibe (Ezetrol®) to ongoing therapy with rosuvastatin (Crestor®) in HIV positive patients not reaching cholesterol targets
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
